Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome
2007 (English)In: Gynecological Endocrinology, ISSN 0951-3590, E-ISSN 1473-0766, Vol. 23, no 5, 257-266 p.Article in journal (Refereed) Published
BACKGROUND: Neurosteroids such as allopregnanolone and pregnanolone are suggested to be of importance for the pathophysiology of premenstrual dysphoric disorder. The aim of this study was to investigate whether the luteal-phase serum concentrations of these neurosteroids are associated with improvement of premenstrual symptoms in 12 women with severe premenstrual syndrome after treatment with low-dose gonadotropin-releasing hormone agonist and placebo. METHODS: Daily ratings for mood and physical symptoms were made prior to treatment and throughout the study. Serum progesterone, allopregnanolone and pregnanolone were assessed in the luteal phase (cycle day -9 to cycle day -1). Based on their symptom ratings, subjects were grouped as either buserelin responders (n = 6) or placebo responders (n = 6). RESULTS: Buserelin responders displayed decreased levels of allopregnanolone (p < 0.05) and progesterone (p < 0.05) in parallel with improvement of symptoms. During the placebo treatment, the placebo responders had lower serum allopregnanolone concentrations than buserelin responders (p < 0.05). This was associated with improvement in symptoms compared with pre-treatment ratings. CONCLUSION: Treatment response, whether induced by buserelin or placebo, appears to be associated with a decrease in allopregnanolone concentration.
Place, publisher, year, edition, pages
2007. Vol. 23, no 5, 257-266 p.
Adult, Buserelin/administration & dosage/*therapeutic use, Cross-Over Studies, Double-Blind Method, Female, Fertility Agents; Female/administration & dosage/*therapeutic use, Humans, Luteal Phase/blood, Placebo Effect, Pregnanolone/*blood, Premenstrual Syndrome/blood/*drug therapy, Progesterone/*blood, Treatment Outcome
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-15036DOI: 10.1080/09513590701253511ISI: 000247686800004PubMedID: 17558683OAI: oai:DiVA.org:uu-15036DiVA: diva2:42807